Table 1 Characterization of clinico-pathological parameters and the frequency of cases with more than one somatic mtDNA ( ATPase6/8 ) mutation in breast cancer patients

Variable

n (%)

n (%)

OR; (95% CI)*

P value

Total number of patients

49

Age at diagnosis (Yrs)

1.482(0.403-5.451)

0.746

<50

19(42.2)

5(26.3)

≥50

26(57.8)

9(34.3)

Histological grade

0.121

I

13(29.5)

1(7.7)

II

24 (54.5)

9(37.5)

III

7(15.9)

3(42.9)

TNM(AJCC) stage

0.680

I

3(6.7)

1(33.3)

II

10(22.2)

2(20.)

III

3(6.7)

0(0)

IV

(64.4)29

11(37.9)

Tumor size(cm)

0.889

<2

5(11.1)

2(40)

2-5

30(66.7)

9(30)

>5

10(22.2)

3(30)

Lymph node status

1.176(0.281-4.926)

1.000

Negative

12(30.8)

4(33.3)

Positive

27(69.2)

10(37)

Lymphatic invasion

1.077(0.281-4.127)

1.000

Negative

18(47.4)

6(33.3)

Positive

20(52.6)

7(35)

Vascular invasion

2.292(0.511-10.284)

1.000

Negative

13(32.5)

4(30.8)

Positive

27(67.5)

10(37)

Estrogen receptor status

0.357(0.075-1.704)

0.222

Negative

8(17.4)

4(50)

Positive

38(82.6)

10(26.3)

Progesterone receptor status

0.938(0.265-3.313)

1.000

Negative

22(48.9)

7(31.8)

Positive

23 (51.1)

7(30.4)

Her-2/neu receptor

1.061(0.285-3.948)

1.000

Negative

30(65.2)

9(30)

Positive

16(34.2)

5(31.3)

P53

0.625(0.166-2.356)

0.526

Negative

23(53.50)

8(34.8)

Positive

20(46.5)

5(25)

Cancer metastasis

3.056(0.718-13.011)

0.191

Negative

18(38.3)

3(16.7)

Positive

29(61.7)

11(37.9)

Overall survival (5 yr%)

18 of 41(43.9)

3(16.7)

0.218(0.049-0.963)

0.051